Trulicity Tracker App
Track Dulaglutide Doses, HbA1c, and Cardiovascular Markers in Shotlee
Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist approved by the FDA in September 2014 for type 2 diabetes. It uses a single-dose autoinjector with a hidden needle — a key advantage for patients with needle aversion. The REWIND trial demonstrated a 12% reduction in cardiovascular events in a broad T2D population. Doses range from 0.75 mg to 4.5 mg weekly.
25,000+
GLP-1 Users Tracking
4.8★
App Rating
Free
Always Free
What Is Trulicity (Dulaglutide)?
Trulicity is the brand name for dulaglutide, a once-weekly GLP-1 receptor agonist developed by Eli Lilly. Unlike liraglutide (a GLP-1 analogue), dulaglutide is a GLP-1 Fc fusion protein — two GLP-1 molecules linked to a modified IgG4 Fc domain. This structure extends the half-life to approximately 5 days, enabling reliable once-weekly dosing without daily injections.
Trulicity is delivered via a single-use, pre-filled autoinjector with a retractable needle that is never visible to the patient. This design has made it one of the most widely prescribed GLP-1 agents for patients with needle aversion. Available in four doses (0.75, 1.5, 3, and 4.5 mg), it offers a broad titration range for both T2D management and modest weight support. The REWIND trial demonstrated cardiovascular benefit in a broad T2D population including patients without prior CV events.
REWIND: CV Benefit in Broad T2D Population
Unlike LEADER and SUSTAIN-6 which enrolled high-CV-risk patients, REWIND enrolled a broader T2D population (31.5% primary prevention). Trulicity still showed a 12% reduction in MACE — extending CV benefit evidence to lower-risk T2D patients.
Trulicity Weekly Dose Escalation
0.75 mg
Weeks 1–4
Starting dose. Inject once weekly on the same day each week. Establish your injection day routine.
1.5 mg
Week 5+ (standard maintenance)
Primary maintenance dose. AWARD-1: -1.51% HbA1c vs placebo at 26 weeks at this dose.
3.0 mg
Week 5+ (if additional control needed)
Higher dose for patients requiring more HbA1c reduction beyond 1.5 mg.
4.5 mg
Maximum dose
Maximum approved dose for patients needing maximum glycaemic effect. Approved in 2020.
Key Clinical Data
HbA1c reduction (AWARD-1)
-1.51%
Mean HbA1c reduction with dulaglutide 1.5 mg at 26 weeks in AWARD-1 vs placebo.
MACE reduction (REWIND)
-12%
Relative reduction in cardiovascular events (HR 0.88, 95% CI 0.79–0.99) in REWIND trial over 5.4 years.
HbA1c reduction (AWARD-4)
-1.64%
HbA1c reduction with dulaglutide 1.5 mg vs insulin lispro in AWARD-4 at 26 weeks.
REWIND Trial Results and AWARD Key Data
| Trial | Comparator | Primary Endpoint | Result |
|---|---|---|---|
| REWIND (N=9,901, 5.4 yrs) | Placebo + standard care | 3-point MACE | HR 0.88 (–12%, p=0.026) |
| AWARD-1 (26 wks) | Exenatide + placebo | HbA1c change (1.5 mg) | -1.51% vs placebo |
| AWARD-4 (26 wks) | Insulin glargine | HbA1c change (1.5 mg) | -1.64% non-inferior |
| AWARD-11 (36 wks) | Dulaglutide 1.5 mg | HbA1c change (4.5 mg) | Additional -0.3% vs 1.5 mg |
| REWIND weight effect | Placebo | Body weight change | -1.5 kg mean vs placebo |
Source: Gerstein HC, et al. Lancet 2019 (REWIND) [1]; Wysham C, et al. Diabetes Care 2014 (AWARD-1).
What to Track in Shotlee
Weekly injections are simpler than daily — but consistent tracking still drives better outcomes with Trulicity.
Weekly Injection Logs
Record each injection: date, dose, and injection site. Log on the same day each week to establish a consistent routine.
HbA1c & Glucose
Enter HbA1c from each clinic visit. Dulaglutide efficacy is best assessed at 3-month intervals when HbA1c stabilises.
Cardiovascular Markers
Log blood pressure, cholesterol, and any CV events. REWIND showed broad CV benefit — track yours over time.
Weekly Weight
Trulicity produces modest weight reduction. Track weekly body weight to quantify your metabolic response.
GI Side Effects
Nausea and diarrhoea peak in the first 2–4 weeks and during dose escalation. Log severity and resolution dates.
Injection Day Tracking
Set a consistent injection day and log any dose shifts. Consistency within 3 days maintains steady-state levels.
Protocol FAQs
Both are once-weekly GLP-1 receptor agonists, but differ in molecule (dulaglutide vs semaglutide), efficacy (semaglutide shows greater HbA1c and weight reduction), and device (Trulicity uses a hidden-needle autoinjector). Ozempic generally outperforms Trulicity on HbA1c and weight in head-to-head trials.
REWIND was a cardiovascular outcomes trial enrolling 9,901 type 2 diabetes patients (including 31.5% without prior CV events) over a median 5.4 years. Dulaglutide reduced 3-point MACE by 12% vs placebo — notably in a broader population than earlier GLP-1 CV trials.
4.5 mg once weekly, approved in 2020. Most patients are started at 0.75 mg and escalated to 1.5 mg for maintenance. The 3.0 mg and 4.5 mg doses are for patients needing additional glycaemic control.
Trulicity produces modest weight loss (approximately 1.5–3 kg in trials). It is not approved for obesity. For dedicated weight management, Mounjaro (tirzepatide) or Zepbound are the preferred options from the same manufacturer.
Yes — Trulicity can be taken on any day of the week as long as doses are at least 3 days apart. If you need to shift your injection day, Shotlee helps you track the new schedule and maintain consistent weekly intervals.
References
- [1]Clinical TrialGerstein HC, et al. "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)." Lancet. 2019;394(10193):121-130.
- [2]Clinical TrialWysham C, et al. "Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes (AWARD-1)." Diabetes Care. 2014;37(8):2159-2167.
Track Your Trulicity Protocol in Shotlee
Log weekly doses, HbA1c, cardiovascular markers, and side effects in the free app built for GLP-1 users.
🚀 Use Shotlee for Free